Table 2.
Univariable and multivariable Cox regression analyses with robust estimator of overall survival and recurrence-free survival after curative resection of solitary HBV-related hepatocellular carcinoma in the entire cohort.
| Overall survival | Recurrence-free survival | |||||||
| Factors | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
| P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | |
| Gender (male/female) | <.001 | 0.535 (0.381–0.753) | .439 | .004 | 0.626 (0.344–0.862) | |||
| Age (>60 vs ≤60, Month) | .009 | 0.579 (0.382–0.879) | .833 | .012 | 0.631 (0.442–0.902) | |||
| Total Bilirubin, umol/L | .215 | .409 | ||||||
| ALT, IU/L | .877 | .175 | ||||||
| Albumin, g/L | .583 | .555 | ||||||
| ΔNLR (>0 vs ≤0) | .124 | .301 | ||||||
| Differentiation (Low, Moderate, High) | <.001 | 0.416 (0.296–0.585) | <.001 | 0.378 (0.267–0.534) | .001 | 0.593 (0.434–0.809) | ||
| MVI (Yes vs No) | <.001 | 4.741 (3.382–6.646) | <.001 | 5.249 (3.589–7.676) | <.001 | 2.244 (1.599–3.147) | <.001 | 4.547 (3.103–6.662) |
| Tumor Size (<5 vs ≥5, cm) | .744 | .888 | ||||||
| Cirrhosis (Yes vs No) | <.001 | 1.832 (1.307–2.568) | .511 | <.001 | 1.769 (1.296–2.416) | .615 | ||
| AFP (≤400 vs >400, ng/mL) | <.001 | 3.074 (2.199–4.297) | <.001 | 2.049 (1.411–2.977) | <.001 | 2.858 (2.105–3.880) | <.001 | 2.136 (1.466–3.110) |
| HBeAg (Positive vs Negative)) | .543 | .152 | ||||||
| HBV-DNA (≥2 × 103 vs 2 × <103, IU/mL) | .237 | .090 | ||||||
| Antiviral Therapy (NtA vs NsA) | .103 | .032 | 0.847 (0.487–0.903) | .038 | 0.899 (0.247–0.935) | |||
| Transfusion (Yes vs No) | .398 | .789 | ||||||
| Complication (Yes vs No) | .013 | 0.551 (0.344–0.882) | 0.230 | .098 | ||||
| Immunotherapy (Tα1 vs none Tα1) | <.001 | 0.512 (0.363–0.721) | <0.001 | 0.370 (0.260–0.528) | <.001 | 0.463 (0.337–0.637) | <.001 | 0.345 (0.242–0.492) |